Cargando…
Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series
AIM: Non-small-cell lung cancer recurs locally 10–40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients. METHODS: We identifie...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356147/ https://www.ncbi.nlm.nih.gov/pubmed/30713586 http://dx.doi.org/10.2217/lmt-2018-0012 |
Sumario: | AIM: Non-small-cell lung cancer recurs locally 10–40% of the time after local therapy, presenting a therapeutic challenge given poor pulmonary reserve. Herein, we seek to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) for retreatment of such patients. METHODS: We identified and reviewed clinical outcomes in ten patients with recurrent non-small-cell lung cancer after past vicryl mesh brachytherapy. RESULTS: Ten patients with a median age of 77 were treated to a median dose of 48 Gy in five fractions. Local control at 1 year was 88%. There was one distant failure at 29 months. There was no significant toxicity after SBRT. CONCLUSION: SBRT is safe and effective when used for re-irradiation after past ablative therapies. |
---|